Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

Type 1 Diabetes Clinical Trial

Official title:

A Feasibility Study of Automated Glucose Control With the Gen2 GlucoSTAT Bionic Pancreas in Volunteers With Type 1 and Type 2 Diabetes

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04227626
• Other study ID #: 2020P000079
• Status: Withdrawn
• Phase: N/A
• Start date: April 2021
• Est. completion date: April 2021

Study information

• Verified date: October 2020
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to perform a first-in-humans trial of a fully integrated, automated, closed-loop blood glucose control system designed for inpatient use. The GlucoSTAT was designed for use by patients with diabetes while they are in the hospital, and others who may develop high blood sugar as a result of their medical problems.

Description:

Our envisioned end product is an in-patient automated closed-loop control system for PG regulation in the ICU as well as on the general hospital wards. In order to qualify the system for the broad spectrum of challenges it will face in the inpatient setting, this study will test the ability of the new integrated configuration of the system (the GlucoSTAT) to control PG in subjects with extremes of insulin sensitivity. The first goal of this study is to test the safety and efficacy of the control system in insulin sensitive subjects with type 1 diabetes. The second goal of this study is to test the safety and efficacy of the control system in subjects with type 2 diabetes and substantial insulin resistance (TDD > 0.75 u/kg/day, with up to 3 subjects with a TDD > 2 u/kg/day).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 2021
• Est. primary completion date: April 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Type 1 diabetes:

1. Age 18 years or older with clinical type 1 diabetes for at least one year.

2. Diabetes currently managed using an insulin infusion pump and rapid- or very-rapid-acting insulins including insulin aspart (NovoLog or Fiasp), insulin lispro (Humalog), and insulin glulisine (Apidra).

3. Total daily dose (TDD) of insulin that is = 1 U/kg

4. Prescription medication regimen stable for at least 1 month.

5. Informed consent obtained before any trial-related activities.

Type 2 diabetes:

1. Age 18 years or older with clinical type 2 diabetes for at least 1 year.

2. Diabetes currently managed using NPH as the basal insulin, which may be supplemented with regular or rapid-acting insulin and/or other anti-diabetic drugs.

3. Total daily dose (TDD) of insulin that is > 0.75 u/kg

• Our goal is to have up to 3 T2D subjects with a TDD > 2 u/kg

4. Prescription medication regimen stable for at least 1 month.

5. Informed consent obtained before any trial-related activities.

Exclusion Criteria:

1. Unable to provide informed consent.

2. Unable to comply with study procedures.

3. Current participation in another diabetes-related clinical trial that, in the judgement of the principal investigator, will compromise the results of this study or the safety of the participant

4. Use of a long-acting insulin (in type 1 diabetes subjects) or a long-acting insulin other than NPH (in type 2 diabetes subjects), including insulin glargine (Lantus), insulin detemir (Levemir), insulin degludec (Tresiba), or ultra-lente.

5. Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception.

6. Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to RF interference.

7. Established history of latex, adhesive, or tape allergy that must be used in the study

8. Inadequate venous access as determined by study nurse or physician at time of screening.

9. Employed by, or having immediate family members employed by Beta Bionics, or being directly involved in conducting the clinical trial, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial.

10. A condition that in the opinion of the investigator could interfere with the safe completion of the study. Conditions to be considered by the investigator may include the following:

• Alcohol or drug abuse

• Use of prescription drugs that may dull the sensorium, reduce sensitivity to symptoms of hypoglycemia, or hinder decision making during the period of participation in the study

• Renal failure

• Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g. climbing a flight of stairs) despite medical management, or within the last 12 months before screening a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting

• Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV

• History of TIA or stroke in the last 12 months

• Untreated or inadequately treated mental illness

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 1 Diabetes
• Type 2 Diabetes Treated With Insulin

Intervention

Device:
• GlucoSTAT
Closed-loop blood glucose control using intravenous insulin and dextrose

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Beta Bionics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average plasma glucose over the closed-loop control period	Average plasma glucose	every 15 minutes for 8.5 hours
Secondary	Number of carbohydrate interventions needed to treat hypoglycemia	The number of times that carbohydrates were consumed in response to hypoglycemia throughout the 8.5 hour experiment	8.5 hour experiment duration
Secondary	Grams of carbohydrates needed to treat hypoglycemia	The amount of carbohydrates consumed in response to hypoglycemia throughout the 8.5 hour experiment	8.5 hour experiment duration
Secondary	Carbohydrate content and total calories of consumed lunch meal	The amount of carbohydrates and total calories the subject consumed during their provided lunch	during 30 minute meal
Secondary	Insulin dosing (u/kg)	Total amount of insulin delivered by the GlucoSTAT during the experiment	8.5 hour experiment duration
Secondary	Dextrose dosing (g/kg)	Total amount of dextrose delivered by the GlucoSTAT during the experiment	8.5 hour experiment duration